<i>TP53</i> suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Gisela Cáceres(Moffitt Cancer Center), Alan F. List(Precision BioSciences (United States))
Cited by 53
Related Papers
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
|International Journal of Molecular Sciences|2023|38
Erythropoietin Receptor Signaling Is Membrane Raft Dependent
|PLoS ONE|2012|32